Search

Search Constraints

You searched for: Author/Creator Berton-Rigaud, D

Search Results

1. 6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial. Issue 10191 (29th June 2019)

2. Safety and dose modification for patients receiving niraparib. (13th August 2018)

3. Long-term fatigue and quality of life among epithelial ovarian cancer survivors: a GINECO case/control VIVROVAIRE I study. (9th March 2019)

4. Safety and dose modification for patients receiving niraparib. (14th May 2018)

5. 938PDNeed for a stratified analysis in stage I malignant ovarian germ cell tumors (MOGCT): Prospective survival analysis of cases collection from the French rare malignant ovarian tumors (TMRO) network & GINECO group. (23rd October 2018)

6. EP1225 How the conformity of surgical practice with the national guidelines improved the quality of management of ovarian granulosa cell tumors (GCT)? A TMRG and GINECO group study. (1st November 2019)

7. Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial. Issue 9 (September 2019)

8. 6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial. Issue 10191 (29th June 2019)